InMed Pharmaceuticals (FRA:MWG) Net Interest Margin (Bank Only) %


FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
29 GF Score
Price €1.40
GF Value €0.78
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:MWG
29GF Score
InMed Pharmaceuticals Inc FRA:MWG
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.40 is trading 79.5% above its estimated GF Value™ of €0.78.

Key valuation signals for FRA:MWG:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.78 vs. price of €1.40 (79.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for FRA:MWG

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price
€0.78
GF Value